Pharmacokinetic Evaluations of the Co-Administrations of Vandetanib and Metformin, Digoxin, Midazolam, Omeprazole or Ranitidine

• Published in: Clinical pharmacokinetics Vol. 53; no. 9; pp. 837 - 847
• Main Authors: Johansson, Susanne, Read, Jessica, Oliver, Stuart, Steinberg, Mark, Li, Yan, Lisbon, Eleanor, Mathews, David, Leese, Philip T., Martin, Paul
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.09.2014; Springer Nature B.V
• Subjects: Adolescent; Adult; Area Under Curve; Digoxin - adverse effects; Digoxin - blood; Digoxin - pharmacokinetics; Drug Interactions; Female; Humans; Internal Medicine; Male; Medicine; Medicine & Public Health; Metformin - adverse effects; Metformin - blood; Metformin - pharmacokinetics; Midazolam - adverse effects; Midazolam - blood; Midazolam - pharmacokinetics; Middle Aged; Omeprazole - adverse effects; Omeprazole - blood; Omeprazole - pharmacokinetics; Original Research Article; Pharmacology/Toxicology; Pharmacotherapy; Piperidines - adverse effects; Piperidines - blood; Piperidines - pharmacokinetics; Quinazolines - adverse effects; Quinazolines - blood; Quinazolines - pharmacokinetics; Ranitidine - adverse effects; Ranitidine - blood; Ranitidine - pharmacokinetics; Young Adult; Omeprazole; Metformin; Midazolam; Digoxin; Ranitidine

Background and Objective Vandetanib is a selective inhibitor of vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR) and rearranged during transfection (RET) signalling, indicated for the treatment of medullary thyroid cancer. We investigated potential drug–dr...